(Total Views: 578)
Posted On: 04/29/2025 10:47:55 AM
Post# of 152159
From ChatGPT
This announcement from CytoDyn is quite significant for several reasons:
Survival Milestones
The fact that they are now reporting 48+ month survival in heavily pre-treated metastatic triple-negative breast cancer (mTNBC) patients is remarkable.
Standard survival for mTNBC after multiple lines of therapy is typically measured in months, not years.
Having four patients with "no evidence of disease" (NED) and another with stable disease at this stage is almost unheard of in this setting. This could attract serious attention at ESMO Breast.
Scientific Credibility and Visibility
Presenting at an ESMO meeting (especially the specialized Breast Cancer conference) gives CytoDyn scientific validation among oncologists, researchers, and pharma companies.
Dr. Richard Pestell presenting is important — he’s a well-known figure in oncology, which lends additional credibility to the poster.
Mechanism of Action (MOA) Spotlight
Mention of an "apparent mechanism of action" in long-term survivors is particularly intriguing.
If they can correlate leronlimab’s effect on CCR5 pathways with survival — especially by showing immune modulation, metastasis suppression, or tumor microenvironment alteration — it could differentiate leronlimab from other therapies.
Follow-Up and Future Monitoring
They are setting up a follow-up protocol for these survivors, which suggests they are planning to generate longitudinal, durable response data — critical for future regulatory filings and partnerships.
Strategic Implications
A strong showing at ESMO Breast could lead to:
Interest from larger pharma (licensing or partnership discussions)
A path toward Breakthrough Therapy Designation (BTD) with the FDA if confirmed in further trials
Raising non-dilutive funding or grants for continued oncology development
In short:
This ESMO poster is not just a formality — it could be the first major scientific step toward positioning leronlimab as a serious player in solid tumor oncology, especially if they clearly document these unprecedented survival outcomes and tie them to an understandable biological mechanism.
This announcement from CytoDyn is quite significant for several reasons:
Survival Milestones
The fact that they are now reporting 48+ month survival in heavily pre-treated metastatic triple-negative breast cancer (mTNBC) patients is remarkable.
Standard survival for mTNBC after multiple lines of therapy is typically measured in months, not years.
Having four patients with "no evidence of disease" (NED) and another with stable disease at this stage is almost unheard of in this setting. This could attract serious attention at ESMO Breast.
Scientific Credibility and Visibility
Presenting at an ESMO meeting (especially the specialized Breast Cancer conference) gives CytoDyn scientific validation among oncologists, researchers, and pharma companies.
Dr. Richard Pestell presenting is important — he’s a well-known figure in oncology, which lends additional credibility to the poster.
Mechanism of Action (MOA) Spotlight
Mention of an "apparent mechanism of action" in long-term survivors is particularly intriguing.
If they can correlate leronlimab’s effect on CCR5 pathways with survival — especially by showing immune modulation, metastasis suppression, or tumor microenvironment alteration — it could differentiate leronlimab from other therapies.
Follow-Up and Future Monitoring
They are setting up a follow-up protocol for these survivors, which suggests they are planning to generate longitudinal, durable response data — critical for future regulatory filings and partnerships.
Strategic Implications
A strong showing at ESMO Breast could lead to:
Interest from larger pharma (licensing or partnership discussions)
A path toward Breakthrough Therapy Designation (BTD) with the FDA if confirmed in further trials
Raising non-dilutive funding or grants for continued oncology development
In short:
This ESMO poster is not just a formality — it could be the first major scientific step toward positioning leronlimab as a serious player in solid tumor oncology, especially if they clearly document these unprecedented survival outcomes and tie them to an understandable biological mechanism.
(19)
(0)Scroll down for more posts ▼
